Andere talen Algernon Pharmaceuticals Inc.

Aandelen

AGN

CA01559R4008

Beurs gesloten - Canadian Securities Exchange Andere beurzen 20:50:41 10-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,125 ^CAD	+13,64%		+13,64%	+92,31%

30/04	Algernon Pharmaceuticals Inc. rapporteert resultaten voor het tweede kwartaal en de zes maanden eindigend op 29 februari 2024	CI
01/04	Algernon Pharmaceuticals zet onderzoeksprogramma naar psychedelische drug DMT beroerte voort als belangrijkste product	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Algernon Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	30/04
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 - 8th, 2024	25/04
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024	24/04
Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar on April 16th, 2024	11/04
Algernon Pharmaceuticals Inc. announced that it has received CAD 0.017 million in funding	10/04
Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 0.017 million in funding	03/04
Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset	01/04
Algernon Pharmaceuticals to Move Forward with Psychedelic Drug Dmt Stroke Research Program as Its Lead Asset	01/04
Algernon Pharmaceuticals Strikes Deal to Advance Ifenprodil in Chronic Cough Treatment	28/03
Algernon Pharmaceuticals Says Acquisition of Ifenprodil Program Completed by US Company	27/03
Canadian Investment Regulatory Organization Trade Resumption - AGN	27/03
Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position	27/03
Canadian Investment Regulatory Organization Trading Halt - AGN	27/03
Algernon Pharmaceuticals Inc. acquired 20% stake in Seyltx, Inc.	27/03
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD	31/01
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD	31/01
Algernon Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended November 30, 2023	25/01
Algernon Pharmaceuticals Inc. Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis	24/01
Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis	11/01
Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis	11/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Algernon Pharmaceuticals Inc.

Aandelen

AGN

CA01559R4008

Andere talen

Filters